Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2. GLP-1 gene (RT-PCR) modulation and its release (EIA) by C. odorata were confirmed in vivo. From the docking result above, TGR5 was identified as a major target for two key C. odorata flavonoids (5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside); sodium taurocholate and C. odorata powder included into the diet of the animals both raised the intestinal GLP-1 expression versus control (p < 0.05); When treated with flavonoid-rich extract of C. odorata (CoF) or malvidin, circulating GLP-1 increased by 130.7% in malvidin-treated subjects (0 vs. 45 min). CoF treatment also resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w., respectively. Conclusions: The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5. This finding may underscore its anti-diabetic potency.
Introduction
The International Diabetes Federation Africa (IDFA) had reported that 14 million Africans are diabetic, with a projection of 34.2 million in 2040 (Foundation 2016) . In 2015, alone, 321,000 diabetes-related deaths were recorded. Given the socioeconomic impact of diabetes, a rapid and highly scalable solution in tackling this epidemic is imperative. Given that most countries in Africa are ranked as low-and medium-income countries, a cost-effective option is an absolute must. Treatment strategy for Type-2 diabetes relies predominantly on improved metabolic status of the patient (Scheen 2003; Scheen and Paquot 2015) while type-1 diabetes is amenable to insulinotropic drugs (Atkinson 2012; D'Alessio 2010) . Current pharmacological intervention is rather inaccessible to patients in low-and medium-income demography due to socioeconomic constraints; thus promoting an argument for alternative therapeutic options if current epidemiology and future projections must be averted.
According to folklore, one of the most effective treatment options for diabetes is extract of Chromolaena odorata L. which has been backed up by some scientific evidence (Adedapo et al. 2016; Onkaramurthy et al. 2013) . Studies linking specific C. odorata phtocompounds to anti-diabetic actions are still scarce; and may delay drug-development plans. This study benefitted from previous phytochemical characterization efforts on C. odorata and the current understanding of clinical and experimental targets for anti-diabetic 1 3
124 Page 2 of 8 drugs. In all, a total of 140 phytocompounds were curated and computationally screened against anti-diabetic targets. Dipeptidyl peptidase (DPP)-4 (Barnett 2006), Takeda-Gprotein-receptor-5 (G protein-coupled bile acid receptor, TGR5) (Genet et al. 2009 ), glucagon-like peptide 1 (GLP1) receptor (Drucker and Nauck 2006), renal sodium dependent glucose transporter (SGLUT)-1/2 (Meng et al. 2008 ) and nucleotide oligomerization domain (NOD)-1/2 (Shiny et al. 2013) were chosen as they represent pharmacological targets for staglipin, 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethyl-4-isoxazolecarboxamide, GLP1, ertugliflozin, and GSK717, respectively, which have proven anti-diabetic potencies.
From the computational studies, 5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside were identified as putative anti-diabetic compounds from C. odorata targeting TGR5. Since both compounds are of flavonoid class, total flavonoid was isolated, validated and tested in vivo for serum GLP-1 release. Since GLP-1 is insulinotropic, flavonoids of C. odorata may therefore represent another therapeutic strategy for managing diabetes (Lokman et al. 2013; Oh 2015; Shen et al. 2012) .
Experimental

Library generation, docking and scoring
Previously identified and characterized compounds of C. odorata were retrieved from PubChem using ChemAxon suite (https ://www.chema xon.com). The library was docked (Autodock Vina) (Seeliger and de Groot 2010) into the active sites of the homology models (https ://swiss model .expas y.org/) (Schwede et al. 2003 ) of DPP-4 (Barnett 2006 ), TGR5 (Genet et al. 2009 ), GLP-1 receptor (Drucker and Nauck 2006), SGLUT-1/2 (Meng et al. 2008 ) and NOD-1/2 (Shiny et al. 2013) . The templates for the model were carefully selected to reflect inhibitor-bound conformation in DPP4 (template = 6B1O, DPP4 in complex with vildagliptin analog, 1.91 Å), SGLUT-1/2 ((template = 3dh4, Crystal Structure of Sodium/Sugar symporter with bound Galactose from vibrio parahaemolyticus, 2.70 Å) (Faham et al. 2008 ) and NOD-1/2 (template = 4JQW, Crystal Structure of a Complex of NOD1 CARD and Ubiquitin, 2.9 Å) (Ver Heul et al. 2014) while TGR5 (template = 3QAK, agonist bound structure of the human adenosine A2a receptor, 2.7A resolution) (Xu et al. 2011 ) and GLP-1 receptor (template = 5NX2, GLP-1R in complex with a truncated peptide agonist, 3.7 A resolution) (Jazayeri et al. 2017) were modeled in active states. In each case, the binding site is defined by 25 cm by 25 cm by 25 cm rectangular box around the mean coordinate of the co-crystallized ligand and in case of NOD without ligand, Nodinitb-1 (ML130, CID 1088438) (Kecek Plesec et al. 2016) retrieved from the PubChem database was docked into the NOD using the BSP-SLIM portal as previously reported (Omotuyi and Ueda 2015) . Lamarckian genetic algorithm (LGA) in AutoDock was used to generate conformations of the C. odorata compounds. Ten docking runs were performed, with an initial population of 150 random individuals and a maximum number of 2,500,000 energy evaluations as successfully implemented in previous studies (Morris et al. 2009 ).
GLP-1 gene expression
All protocols related to animal studies were approved by the Animal Ethics Committee of Centre for Research and Development (CRD), Adekunle Ajasin University, AkungbaAkoko. C. odorata powder (n = 5) and sodium taurocholate (Sigma-Aldrich, n = 5) were formulated into rat feed (5%, feed 95%), and compared with the control (feed = 100%, n = 3). The bitter taste of the treatments was masked using locally sourced honey (100 ml/100 g formulated fed and control group). Animals were allowed to feed ad libitum for 14 h followed by 8 h feed withdrawal. RNA was isolated from the proximal end of the ligated ileum using TRIzol Reagent (ThermoFisher Scientific). DNA contaminant was removed following DNAse I treatment (ThermoFisher Scientific) following manufacturer's protocol. Purified DNA-free RNA was converted to cDNA immediately using ProtoScript ® First Strand cDNA Synthesis Kit (NEB). PCR amplification was done using OneTaq® 2X Master Mix (NEB) using the following primer set: (GLP-1-Forward-primer-5′-TCC CAA AGG AGC TCC ACC TG-3′/Reverse-primer-5′-TTC TCC TCC GTG TCT TGA GGG-3′; β-Actin-(control)-β-Actin-Fowardprimer-5′-GTC GAG TCC GCG TCCAC-3′/Reverse-primer-5′-AAA CAT GAT CTG GGT CAT CTT TTC ACG-3′). GLP-1. Representative snapshot of reverse transcription polymerase chain reaction-agarose gel electrophoresis data of Na-taurocholate (Na-T) and C. odorata fed Wistar rats. The band density (Image-J) (Schneider et al. 2012 ) is plotted as a bar graph (mean ± SEM, n = 3-5).
Flavonoid isolation, characterization, and serum GLP-1 estimation
Flavonoids were isolated from fresh samples of C. odorata using HCL (1%, v/v) as previously documented (Omotuyi et al. 2013 ) and purified using DOWEX-50 column (Raman et al. 2004 ) resulting in C. odorata flavonoids (CoF). CoF HPLC characterization has been described elsewhere (Mattila et al. 2000) . Serum GLP-1(EIA, according to the manufacturer's protocol) was assayed before (0 min) and after oral administration (45 min) of CoF (n = 5), and compared to malvidin chloride (MaL, n = 5) (Sigma-Aldrich) and untreated control animals (n = 3) as previously described (Phuwamongkolwiwat et al. 2014) .
Results and discussion
Dysregulated glucose homeostasis underlies diabetes mellitus and its microvascular complications. Glucose homeostasis may be altered by autoimmune destruction of pancreatic beta cells or insulin resistance. Therefore, diabetic patients have benefitted from exogenous insulin, treatment strategies that improve endogenous insulin production, reduce obesity and restores energy balance. GLP-1 secretagogues (acting via TGR5 activation) (Cao et al. 2016 ) and GLP-1 analogs are particularly interesting in clinical settings as they enhance the biological actions of GLP-1 such as promoting β cells proliferation and function (insulin synthesis and GLP-1 receptor-mediated insulin secretion), suppressing gut motility and appetite. GLP-1 is short-lived, rapidly metabolized by serum DPP-4 (Beck-Nielsen 2012; Lee 2016; Yu et al. 2015) . Another clinically useful strategy is to elongate GLP-1 by inhibiting DPP-4 (Yu et al. 2015) . Recently, NOD-like receptors (NOD1 and NOD2) are now recognized as critical factors in HFD (high-fat diet)-induced pancreatic inflammation and insulin intolerance (Schertzer et al. 2011 ) and the clinical application of its antagonists is now under intensive investigation (Moreno and Gatheral 2013) . Another clinical target for diabetes is the sodium-glucose co-transporter (SGLT)-2 (Mudaliar et al. 2015) . Inhibitors of SGLT2 prevent renal glucose reabsorption enhances urinary glucose excretion with concomitant reduction in plasma glucose levels (Fig. 1) .
Identification of TGR5 as C. odorata phytocompounds target
The first question in this study is which of these targets may explain the anti-diabetic potency of C. odorata? To answer this, a library of 140 phytocompounds was created for C. odorata (supplementary information 1) based on previous reports of isolation and structural characterization. Docking results for each targets detailed above are represented as a heat map (Fig. 2a) . Although, several phytochemicals of C. odorata have high affinity (− 9.0 to − 12.0 kcal/mol; yellow to red spectrum) for TGR5, GLP1R and SGLT1, It is of interest to note that 5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside are further interest as they showed the lowest binding energy overall for TGR5; calculated as − 11.5 and − 11.0 kcal/mol, respectively, compared with − 9.4 kcal/mol for 6α-Ethyl-23(S)-methylcholic Acid (INT-777) a well-studied TGR5 agonist. To validate the computational data obtained for TGR5, 45 agonists with EC 50 records were downloaded from the ChemBL database, prepared and docked into the TGR5 model used for C. odorata screening. A line graph of experimental p value − 1.5 with the correlation coefficient (r 2 ) = 0.75 (Fig. 2b) . Next, the binding poses were studied to determine the residues involved in TGR5 interaction. INT-777 relied on hydrophobic interaction with Phe-96, Tyr-89, Leu-141, Leu-244, Leu-266, Leu-71 and hydrophobic interaction with Asn-77 (Fig. 3a) . The fused rings of 5,7-dihydroxy-6-4-dimethoxyflavanone is stabilized by hydrophobic interaction with Leu-262/266 Fig. 1 Graphical abstract. The contribution of pancreas, intestinal L-cell, kidney and blood factors in the development of novel anti-diabetic agents residues. The detached A-ring forms hydrophobic interaction with Pro-164 and Leu-168. Ser-156 and Tyr-240 may also play key roles in stabilizing the interaction between TGR5 and 5,7-dihydroxy-6-4-dimethoxyflavanone (Fig. 3b) . Homoesperetin-7-rutinoside tends to utilize all the residues highlighted in INT-777 and 5,7-dihydroxy-6-4-dimethoxyflavanone complexes and may also benefit from enhanced hydrophilic interaction resulting from the presence of rutinoside residue (Fig. 3c) . While further experimental study was focused on TGR5 effects, it is worthy of note to add that homoesperetin-7-rutinoside also demonstrated low binding energy for GLP1R (− 11.0 kcal/mol) and quercetin 3-O-rutinoside show a low binding energy for SGLT1 (− 11.0 kcal/mol) but not SGLT2 (− 9.8 kcal/mol, binding pose not shown).
Diet-included C. odorata alters GLP-1 gene expression in the ileum
If TGR5 is indeed a key target of C. odorata phytocompounds, then it should promote GLP-1 gene expression profile, therefore, C. odorata powder and sodium taurocholate (Na-T) were introduced into the feed of the subjects as described in the experimental section followed by determination of GLP-1 gene expression in proximal end of the ligated ileum. In the treatment groups, GLP-1 was significantly upregulated (n = 3-5 animals, p > 0.05 vs. untreated control) but no statistically significant difference was observed between sodium taurocholate and C. odorata treatments (Fig. 4) . This finding further lends credence to the anti-diabetic effects of dietary flavonoids and further reveals a possible mechanism via enhanced GLP-1 production, insulin secretion, pancreatic β-cells proliferation. Ultimately resulting in hypoglycemia, reduced insulin resistance and increased glucose uptake in skeletal muscle and white adipose tissue (Babu et al. 2013 ). The result is consistent with previous findings that phenolics from berries upregulated insulin-like growth factor 1 receptor, insulin-like growth factor 2, insulin-like growth factor binding proteins, vascular endothelial growth factor (VEGF) and GLP-1 genes in iNS-1E cells (Johnson and de Mejia 2016) .
C. odorata flavonoid improves plasma GLP-1
5% C. odorata in rat feed is a complex mixture of several phytochemicals and increased in GLP-1 gene expression may not be due to flavonoids alone. Therefore, heterogeneous flavonoids from fresh samples of C. odorata (CoF) were isolated as described previously (Omotuyi et al. 2013 ) and purified (Raman et al. 2004 ). Flavonoids   Fig. 3 Binding poses of select C. odorata phytochemicals in the orthosteric site of TGR5. 6α-Ethyl-23(S)-methylcholic Acid (INT-777, cyan stick representation), a known TGR5 (green cartoon) agonist was docked into TGR5 model using BSP-SLIM method and re-docked using Autodock Vina for validation (a). 5,7-dihydroxy-6-4-dimethoxyflavanone ( Fig. 2b ; pink stick representation) and Homoesperetin-7-rutinoside ( Fig. 2c ; yellow stick representation) were docked (Autodock Vina) into TGR5 using INT-777 as reference ligand. Residues participating in the interaction of each ligand are displayed on top of each complex Fig. 4 Intestinal GLP-1 expression in C. odorata fed Wistar rats. Representative snapshot of reverse transcription polymerase chain reaction-agarose gel electrophoresis data of Na-taurocholate (Na-T) and C. odoata fed Wistar rats. The band density (Image-J) (Schneider et al. 2012 ) is plotted as a bar graph (mean ± SEM, n = 3-5) from C. odorata absorbed at 230/530 nm following HPLC fractionation (Fig. 5) . CoF was compared with malvidin chloride (MaL) and untreated control animals for plasma GLP-1 release as previously described (Phuwamongkolwiwat et al. 2014 ). Blood was drawn from animals (0 min, female Wistar rats, 8 weeks old, n = 3) previously fasted for 24 h and following 1 mL oral doses (0 (water, control), 30 (MaL), 10, 30 (CoF) mg/kg b.w.) of treatment materials after 45 min post administration. GLP-1 data showed no significant difference in the circulating GLP-1 in the pretreated animals, but following MaL (30 mg/kg), circulating GLP-1 levels increased by 130.7% (vs. water control). CoF treatment resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w, respectively, in comparison with the watertreated control (Fig. 6) . Post-treatment, circulating GLP-1 is significantly higher in b.w) group compare with the MaL-treated animals (Adjusted P value = 0.04, inset, Fig. 6 ). This data lend credence to the previous reports that non-nutritive components of plant especially the flavonoid class have GLP-1 secretory properties. The authors specifically identified delphinidin 3-rutinoside (D3R) as GLP-1 secretagogue in GLUTag L cells (Kato et al. 2015) . Furthermore, aromatic ring of flavonoids containing three hydroxyl, two methoxyl moieties, or rutinose may be essential for GLP-1 stimulation. Although this study relied on computation for proposing the plausible target for C. odorata flavonoids, Kato et al. (Kato et al. 2015) suggested that D3R stimulated GLP-1 secretion in GLUTag cells via GPR40/120-mediated Ca 2+ -CaMKII pathway.
Conclusion
This study investigated the putative anti-diabetic principle in C. odorata and its underlying mechanisms using in silico and in vivo experiments. 5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside are the major C. odorata compounds with high affinity for TGR5. Normal rats fed C. odorata-based food or administered flavonoid-rich extract of C. odorata showed increased blood GLP-1 release compared with their control littermates.
Interestingly, the results demonstrate that C. odorata may 
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